Last updated on February 2018

Transposon-manipulated Allogeneic CARCIK-CD19 Cells in Pediatric and Adult Patients With r/r ALL Post HSCT

Brief description of study

This is a single arm, open-label, multi-center, phase 1-2a study to determine the Maximum Tolerated Dose and/or the Recommended Phase 2 Dose and the safety of CARCIK-CD19 in adult and pediatric patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Clinical Study Identifier: NCT03389035

Contact Investigators or Research Sites near you

Start Over

Alessandro Rambaldi, Prof.

Ospedale PG23
Bergamo, Italy
  Connect »

Andrea Biondi, Prof.

Fondazione MBBM
Monza, Italy
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.